KMKarl Mann

Karl Mann

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Karl Mann has a total of 15 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Consultation–Liaison Psychiatry in General Hospitals: Improvement in Physicians’ Detection Rates of Alcohol Use Disorders

    by Alexander Diehl, Helmut Nakovics, Bernhard Croissant, Iris Reinhard, Falk Kiefer, Karl Mann


    • 1 January 2008
      • Vol. 22  (4) , 243-51

    [Recent results in relaps prevention of alcoholism with Disulfiram].

    by Jochen Mutschler, Alexander Diehl, Christian Vollmert, Hans Herre, Karl Mann, Falk Kiefer

    For more than 50 years, disulfiram has been approved for the treatment of chronic alcohol dependence. In the last years there has been observed an increase in the prescription of disulfiram in germany. It acts as a psychological deterrence of a possible disulfiram-alcohol reaction. This paper describes the current clinical impact and possible future of disulfiram. Clinical trials using disulfiram for the treatment of alcohol dependence were discussed. Furthermore, the options of combining disulfiram with novel anti-craving agents were considered. Moreover, experiences and results of a cross section of the Mannheimer Disulfiram program will be presented. Nowadays there exists consent in the matter that Disulfiram should only be adminsitered as part of a comprehensive therapy program, this means in the context of an intake under medical supervision. This paper is supposed to help estimate the value of disulfiram in recent addiction medicine.


  • A Pilot Study of Oxcarbazepine Versus Acamprosate in Alcohol‐Dependent Patients

    by Bernhard Croissant, Alexander Diehl, Oliver Klein, Sergio Zambrano, Helmut Nakovics, Andreas Heinz, Karl Mann

    Objectives: This pilot study has been designed to collect preliminary data on the use of a new antiepileptic drug in the management of alcoholic patients. Oxcarbazepine (OXC) blocks voltage‐sensitive sodium channels. Its metabolite reduces high‐voltage–activated calcium currents in striatal and cortical neurons, thus reducing glutamatergic transmission at corticostriatal synapses. This reduction is of interest in the treatment of alcohol dependence, as acamprosate (ACP) modulates NMDA receptors, resulting in an inhibition of glutamatergic transmission. Furthermore, OXC has revealed a mood‐stabilizing effect in bipolar affective disorders. We have compared OXC with ACP in relapse prevention in recently withdrawn alcohol‐dependent patients. Methods: We investigated the efficacy and safety of OXC (vs ACP) by conducting a 24‐week randomized, parallel‐group, open‐label, clinical trial on 30 acutely detoxified alcoholic patients. Survival analyses (Kaplan–Meier) were performed to look for evidence of a longer “survival” of patients receiving OXC. We assessed time to first severe relapse and additional secondary endpoints. Results: After withdrawal, time to severe relapse and time to first consumption of any ethanol by OXC patients were not longer than for ACP patients. Abstinent patients in both study groups showed a significantly lower obsessive compulsive drinking scale—German version (OCDS‐G) than relapsed patients. No undesired effects occurred when OXC patients consumed alcohol. Conclusion: Our findings indicate that it could be worthwhile to test relapse prevention using OXC in an adequate sample. While the current sample size clearly limits further conclusions from this pilot study, it is noteworthy that OXC is well tolerated, even when alcohol is on board. Thus, in medication‐based relapse prevention, OXC could be a promising alternative for alcoholic patients unable to benefit from ACP or naltrexone or those who have affective liability. OXC certainly merits a larger placebo‐controlled trial.


  • QUETIAPINE IN ALCOHOL RELAPSE PREVENTION - A CASE SERIES.

    by Bernhard Croissant, Alexander Diehl, Lucie Severa, Helmut Nakovics, Eckard Klages, Derik Hermann, Karl Mann


  • OXCARBAZEPINE IN ALCOHOL RELAPSE PREVENTION ??? A RANDOMIZED OPEN PILOT STUDY.

    by Bernhard Croissant, Alexander Diehl, Lucie Severa, Oliver Klein, Helmut Nakovics, Sergio Zambrano, Andreas Heinz, Karl Mann